Fig. 4From: Effectiveness and safety of omalizumab in patients with allergic bronchopulmonary aspergillosis with or without allergic rhinitis: a retrospective chart reviewBlood eosinophil count (cells/µL) (a) and total serum IgE level (kU/L) (b). Blood eosinophil count (cells/µL) (a) and total serum IgE level (kU/L) in patients with or without allergic rhinitis (AR) before and after omalizumab administration. *p < 0.05. ***p > 0.05Back to article page